In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medytox Inc.

www.medytox.com

Latest From Medytox Inc.

Suspicions Raised Over Medytox’s Botulinum Toxin Amid Ongoing Court Battle

Shares of Korea's Medytox fell on suspicions that it supplied botulinum toxin to local hospitals before the product's approval in 2006. The concerns add to other manufacturing issues that have been denied by the company, which pointed to a rival as the possible source amid an ongoing legal battle over the strain used in the product.

South Korea Aesthetics

With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share

Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.

Approvals Launches

Biosimilars A Driving Force Behind Korean Pharma Exports

Remsima/Inflectra's rapid penetration into global biosimilar markets is helping Celltrion to grow into a global biologics powerhouse and also boosting South Korea's pharma exports. The country has logged a biologics trade surplus for the first time in years, due mainly to a surge in exports of biosimilar infliximab, and trend only set to continue with more approvals and launches on the horizon.

BioPharmaceutical Asia Pacific

Medytox In China JV Deal, Aims To Set Up More Asian Units

After the establishment of its first overseas subsidiary in Taiwan early this year, Medytox has set up a joint venture with China's Bloomage BioTechnology to sell its botulinum toxin products and hyaluronic acid fillers in China. The South Korean biopharma company is aiming to establish more subsidiaries in other major Asian countries as part of plans to directly sell its products in the region.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Medy-Tox Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Medytox Inc.
  • Senior Management
  • Hyunho Jung, PhD, CEO
  • Contact Info
  • Medytox Inc.
    Phone: (82) 432171555
    78 Gangni 1-gil, Ochang-eup
    Cheongwon-gu
    Chungcheongbuk-do,
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register